Funder: European Commission
Due Dates: May 22, 2025 (Opening) | September 16, 2025 (Deadline)
Funding Amounts: €8,000,000–€10,000,000 per project; approx. 5 grants; Horizon Research and Innovation Actions (RIA)
Summary: Supports research to engineer allogeneic human cell therapies using genomic and gene editing tools, targeting major therapeutic challenges and enabling safer, more effective treatments.
Key Information: Proposals must focus on one therapeutic area and exclude exogenous drug loading; collaboration with SMEs and regulatory engagement encouraged.